Geode Capital Management LLC Sells 11,723 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Geode Capital Management LLC lessened its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 0.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,193,505 shares of the biopharmaceutical company’s stock after selling 11,723 shares during the quarter. Geode Capital Management LLC’s holdings in TG Therapeutics were worth $96,145,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the business. Blue Trust Inc. boosted its holdings in shares of TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 371 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp grew its position in shares of TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock valued at $64,000 after acquiring an additional 1,737 shares during the period. Synergy Asset Management LLC purchased a new stake in shares of TG Therapeutics during the 4th quarter worth approximately $75,000. Finally, GAMMA Investing LLC raised its holdings in shares of TG Therapeutics by 562.4% in the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 2,171 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX opened at $35.98 on Friday. The stock’s 50-day moving average is $35.68 and its 200 day moving average is $31.29. The stock has a market cap of $5.65 billion, a price-to-earnings ratio of -359.76 and a beta of 2.14. TG Therapeutics, Inc. has a 1-year low of $12.93 and a 1-year high of $43.32. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TGTX has been the topic of several research reports. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.